Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design |
| |
Authors: | Yong Wha Moon Sun Young Rha Hei-Cheul Jeung Chan Kim Min Hee Hong Hyun Chang Jae Kyung Roh Sung Hoon Noh Byung Soo Kim Hyun Cheol Chung |
| |
Institution: | 1. Cancer Metastasis Research Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, 120-752, Korea 2. Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea 3. Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea 4. Division of Medical Oncology, Department of Internal Medicine, Kangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea 5. Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
|
| |
Abstract: | Purpose We analyzed the natural history of advanced gastric cancer with sequential salvage chemotherapy following first-line treatment. Methods We studied 532 patients with unresectable gastric adenocarcinoma who were treated at Yonsei Cancer Center (2000–2008). The patients were managed with multiple sequential salvage chemotherapy as allowed by performance status and toxicity profiles. The tumor response was assessed every two cycles. Results Four hundred sixty patients received palliative chemotherapy and 72 received supportive care only. The median overall survival was 12.0 months for all patients, 12.1 months for the chemotherapy group, and 2.5 months for the supportive care group (P < 0.001). In the chemotherapy group, 87% received first-line chemotherapy, 47% second-line, 23% third-line, 9% fourth-line, and 3% fifth-line. Response rates were 24.8, 12.6, 10.9, 2.6, and 0% and disease control rates were 76.3, 60.1, 54.2, 54.2, and 53.3% for first- to fifth-line treatment, respectively. The median progression-free survival was 5.5, 3.4, 2.5, 1.9, and 2.0 months and overall survival was 12.1, 7.9, 5.5, 5.0, and 6.8 months. Performance status and metastatic pattern were consistent prognostic factors throughout salvage treatment. Conclusions Clinical trials may be feasible in second- or third-line salvage chemotherapy for gastric cancer. Future clinical trials in these settings should take into account the low response rate, short progression-free survival, and the prognostic factors for optimal trial design. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|